SLAMF7、KIR、CD137、PD-1/PD-L1、CD38の可能性

SLAMF7

KIR

CD137

PD-1/PD-L1

CD38

参考文献

4) Bae J, et al. Dendritic cells and peptide-based vaccine in multiple myeloma. In: Munshi NC, Anderson KC, eds. Advances in Biology and Therapy of Multiple Myeloma: Volume 2: Translational and Clinical Research. New York, NY: Springer Science+Business Media; 2013:131-154.

5) Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(3):315-325.

6) Carbone E, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105(1):251-258.

7) Murillo O, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008;14(21):6895-6906.

8) Gullo C, et al. Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One. 2010;26(5):e10845..

このサイトは、患者の皆様やご家族の方などを対象にブリストル・マイヤーズ スクイブ株式会社の医療用医薬品を正しくご理解いただくために作成したものです。